FDA approves biosimilar adalimumab
There are “no clinically meaningful differences” between Amgen’s biosimilar adalimumab (Amjevita) and AbbVie’s branded product Humira, the Food and Drug Administration noted it its Sept. 23 announcement of Amjevita’s approval.
Although Amjevita (adalimumab-atto) is expected to cost less than...
Source: Skin and Allergy News - Category: Dermatology Source Type: news
More News: Allergy | Allergy & Immunology | Dermatology | Food and Drug Administration (FDA) | Humira | Skin